resources securing-and-implementing-a-transformative-agreement 
Drug Discovery World
JANUARY 31, 2023
Robust digital workflows can reduce errors and time to compile data leading to greater transparency, faster reporting and help biopharmaceutical companies reach regulatory submission faster. Ken Forman , Senior Director of Product Strategy, IDBS explains. Savvy organisations anticipate these challenges early in the drug approval process.
Drug Discovery World
OCTOBER 20, 2022
In June 2022, a basic policy was established for a “Digital Garden City Nation”, an initiative which aims to achieve “rural-urban digital integration and transformation” 2. Implementing digital services to solve rural issues. Developing and securing human resources with digital skills. Government policies .
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 18, 2020
I am pleased to join AVEO during this transformational period for the Company, as it prepares for the potential launch of tivozanib in the U.S.,” We are excited to welcome David to the AVEO team as we continue to prepare for the potential commercial launch of tivozanib in the U.S.,” said Mr. Crist. “I Mr. Crist holds a B.S.
pharmaphorum
JANUARY 3, 2023
A potential solution could be provided by decentralised storage, which could not only improve data security, but also open opportunities for business process automation, improved data governance, and potentially new revenue streams. Is there anything that can be done about this? What is decentralised storage?
The Pharma Data
FEBRUARY 8, 2021
Q4 2020 sales growth (2) of 4.2% and business EPS growth of 9.8% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% to €982 million). Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. General Medicines declined 7.5%, reflecting lower U.S. Sales down 2.4%
The Pharma Data
FEBRUARY 4, 2021
Q4 2020 sales growth (2) of 4.2% and business EPS growth of 9.8% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% to €982 million). Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. General Medicines declined 7.5%, reflecting lower U.S. Sales down 2.4%
XTalks
SEPTEMBER 14, 2020
Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. By the end of August, the World Health Organization (WHO) counted 33 vaccine candidates in some stage of clinical trial evaluation. The price of that prize is incalculable.
Expert insights. Personalized for you.
98 
Let's personalize your content